Efficacy and safety of ledipasvir/ sofosbuvir for the treatment of chronic hepatitis c in persons with sickle cell disease

Juhi Moon; Robert H. Hyland; Fangqiu Zhang; Diana M. Brainard; Sophie Lanzkron; John G. McHutchison; Mark Sulkowski

doi:10.1093/cid/cix441

Efficacy and safety of ledipasvir/ sofosbuvir for the treatment of chronic hepatitis c in persons with sickle cell disease

Juhi Moon, Robert H. Hyland, Fangqiu Zhang, Diana M. Brainard, Sophie Lanzkron, John G. McHutchison, Mark Sulkowski

School of Medicine

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Patients with sickle cell disease are at high risk for chronic hepatitis C infection. Prior treatment has been limited due to the use of ribavirin causing hemolytic anemia and interferon causing cytopenias. We demonstrate the safety and efficacy of fixed-dose combination ledipasvir and sofosbuvir for 12 weeks in this population.

Original language	English (US)
Pages (from-to)	864-866
Number of pages	3
Journal	Clinical Infectious Diseases
Volume	65
Issue number	5
DOIs	https://doi.org/10.1093/cid/cix441
State	Published - Sep 1 2017

Keywords

HCV
Hepatitis C infection
LDV/SOF
Ledipasvir
Sickle cell disease

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1093/cid/cix441

Cite this

@article{d7ecdc043b204e04ab26aa538fc05910,

title = "Efficacy and safety of ledipasvir/ sofosbuvir for the treatment of chronic hepatitis c in persons with sickle cell disease",

abstract = "Patients with sickle cell disease are at high risk for chronic hepatitis C infection. Prior treatment has been limited due to the use of ribavirin causing hemolytic anemia and interferon causing cytopenias. We demonstrate the safety and efficacy of fixed-dose combination ledipasvir and sofosbuvir for 12 weeks in this population.",

keywords = "HCV, Hepatitis C infection, LDV/SOF, Ledipasvir, Sickle cell disease",

author = "Juhi Moon and Hyland, {Robert H.} and Fangqiu Zhang and Brainard, {Diana M.} and Sophie Lanzkron and McHutchison, {John G.} and Mark Sulkowski",

year = "2017",

month = sep,

day = "1",

doi = "10.1093/cid/cix441",

language = "English (US)",

volume = "65",

pages = "864--866",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Efficacy and safety of ledipasvir/ sofosbuvir for the treatment of chronic hepatitis c in persons with sickle cell disease

AU - Moon, Juhi

AU - Hyland, Robert H.

AU - Zhang, Fangqiu

AU - Brainard, Diana M.

AU - Lanzkron, Sophie

AU - McHutchison, John G.

AU - Sulkowski, Mark

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Patients with sickle cell disease are at high risk for chronic hepatitis C infection. Prior treatment has been limited due to the use of ribavirin causing hemolytic anemia and interferon causing cytopenias. We demonstrate the safety and efficacy of fixed-dose combination ledipasvir and sofosbuvir for 12 weeks in this population.

AB - Patients with sickle cell disease are at high risk for chronic hepatitis C infection. Prior treatment has been limited due to the use of ribavirin causing hemolytic anemia and interferon causing cytopenias. We demonstrate the safety and efficacy of fixed-dose combination ledipasvir and sofosbuvir for 12 weeks in this population.

KW - HCV

KW - Hepatitis C infection

KW - LDV/SOF

KW - Ledipasvir

KW - Sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=85032224034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032224034&partnerID=8YFLogxK

U2 - 10.1093/cid/cix441

DO - 10.1093/cid/cix441

M3 - Article

C2 - 28505305

AN - SCOPUS:85032224034

SN - 1058-4838

VL - 65

SP - 864

EP - 866

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 5

ER -

Efficacy and safety of ledipasvir/ sofosbuvir for the treatment of chronic hepatitis c in persons with sickle cell disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this